Menu
No results found.
Weekly Share Price & Valuation Overview
NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- INR 156.63B
- Enterprise Value Operating value: market cap + total debt − cash.
- INR 134.49B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- INR 43.96B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- INR 36.53B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- INR 19.63B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- INR 245.42
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 94.79
- Shares Outstanding
- 179.11M
- Float Shares
- 81.33M
- Implied Shares Outstanding
- 179.27M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
38.63%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
44.64%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
83.11%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
38.62%
- Revenue Growth Year-over-year revenue growth.
-
-2.50%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-28.10%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-28.10%
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.04
- Total Cash Cash and equivalents.
- INR 24.97B
- Total Debt Short + long-term interest-bearing debt.
- INR 2.79B
- Net Debt Net Cash Total debt − cash (negative = net cash).
- INR -22.17B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.14
- Dividend Yield suppressed due to an anomalous value from the feed (>30%).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.